MedTrace Logo

Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults

NCT00002427 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and effectiveness of 9 doses of HU in order to find the best dose of HU to use with ddI and d4T in fighting HIV infection.

HU plus ddI plus d4T appears to be a suitable anti-HIV drug combination for long-term control of HIV. This combination can sharply decrease viral load (level of HIV in the body) with few side effects, making it easy to take.

Conditions

  • HIV Infections

Interventions

DRUG

Hydroxyurea

DRUG

Stavudine

DRUG

Didanosine

Sponsors & Collaborators

  • Research Institute for Genetic and Human Therapy

    lead OTHER

Principal Investigators

  • Franco Lori

  • Julianna Lisziewicz

Study Design

Purpose
TREATMENT
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002427 on ClinicalTrials.gov